

 Project Number 874700	Title VANGUARD Communication Portfolio	Deliverable Number D9.4
		Version 2

H2020-SC1-2019-Single-Stage-RTD

VANGUARD - New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Deliverable D9.4

VANGUARD Communication Portfolio

WP 9 – Stakeholder engagement, dissemination and exploitation

Authors: Julia Goetz & Marco Cavallaro (accelCH)

Lead participant: accelCH

Delivery date: 31.10.2022

Dissemination level: Public

Type: Report



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 874700.

 Project Number 874700	Title VANGUARD Communication Portfolio	Deliverable Number D9.4
		Version 2

Revision History

Author Name, Partner short name	Description	Date
Julia Goetz (accelCH)	Draft deliverable	02/05/2022
Marco Cavallaro (accelCH)	Review	30/06/2022
Julia Goetz (accelCH)	Final version	01/07/2022
Julia Goetz (accelCH)	Final version 2, based on PO review All VANGUARD publications include the acknowledgement to Horizon 2020 according to Article 29.4 of the Grant Agreement.	28/10/2022

 Project Number 874700	Title VANGUARD Communication Portfolio	Deliverable Number D9.4
		Version 2

Contents

PROJECT PARTNERS	3
EXECUTIVE SUMMARY	4
1 INTRODUCTION	5
2 COMMUNICATION PORTFOLIO AREAS	6
2.1 Outreach	6
2.1.1 VANGUARD in the media	6
2.1.2 Public Relations.....	7
2.1.3 Visual elements	8
2.1.4 Social media	9
2.2 Outcomes.....	10
2.2.1 VANGUARD workshops.....	10
2.2.2 Scientific publications	11
2.2.3 Public Reports	12
2.3 Members' area.....	13
2.3.1 Project Handbook	13
2.3.2 Stakeholder Engagement and Dissemination Plan	13
2.3.3 Templates	14
3 OUTLOOK	14
ANNEX: SCREENSHOTS OF THE COMMUNICATION PORTFOLIO	15

Project Partners

accelCH	accelopment AG
CHU-LYON	Lyon Claude Bernard University
EMC	Erasmus University Medical Centre
ESOT-ELPAT	European Society for Organ Transplantation
KGM	Kugelmeiers AG
LMUM	Ludwig-Maximilians-Universität München
OSR	IRCCS Ospedale San Raffaele
UNIGE	University of Geneva
UNIUPO	Università degli Studi del Piemonte Orientale "Amedeo Avogadro"

 Project Number 874700	Title VANGUARD Communication Portfolio	Deliverable Number D9.4
		Version 2

Executive Summary

This deliverable consists of the VANGUARD communication and dissemination materials which, combined, create the VANGUARD communication portfolio. The created material serves as a helpful tool for project partners to facilitate communication and dissemination to various target audiences.

Need for the Deliverable

In order to disseminate VANGUARD project information and results, a variety of activities and materials have been defined and documented in the deliverable D9.2 Stakeholder Engagement and Dissemination Plan (SEDP) which was submitted in February 2021. The deliverable D9.4 VANGUARD Communication Portfolio is an update of the implemented activities originally defined in the SEDP to ensure the efficient and effective implementation of planned activities. It further documents where the materials can be found so that information on the VANGUARD project is easily accessible for internal and external stakeholders.

Objectives of the Deliverable

With the help of this deliverable we want to:

- Create a first source of project information for stakeholders
- Facilitate dissemination activities
- Offer easy modifiable templates
- Increase awareness of VANGUARD
- Increase the project's impact
- Define guidelines for communication
- Promote a uniform visual identity

Outcomes

The key areas of the Communication Portfolio can be found online via the links below:

- [Outreach](#) (public access): Communication and outreach focus, targeted towards patients, the general public and media (Public access).
- [Outcomes](#) (public access): Dissemination oriented, targeted towards the scientific community, healthcare and patient advocacy groups.
- [Members area](#) (closed access) communication: For internal stakeholders of the VANGUARD network, supporting materials to facilitate the implementation of communication and dissemination measures.

Next steps

The content and specific areas of the Communication Portfolio will be updated on a regular basis to include the latest updates and materials created for VANGUARD. The specific activities that will be implemented and developed are documented in the SEDP.







Over the timespan of VANGUARD, project- or target group-related factors may change. Some activities will prove effective, others less. As the consortium is dedicated to reach maximum impact, repeated evaluation and adjustment are necessary, based on feedback loops per activity. The monitoring, evaluation and improvement procedure will take place at relevant points of time during the project or periodically, depending on the activity's evaluation method.

 Project Number 874700	Title VANGUARD Communication Portfolio	Deliverable Number D9.4
		Version 2

1 Introduction

A key feature of the VANGUARD project will be the communication of information and dissemination of project results (WP9) throughout the project duration. To reach selected stakeholders as well as creating a recognisable and uniform project identity, accelCH in collaboration with all VANGUARD project partners has developed VANGUARD communication and dissemination materials in order to facilitate outreach activities to key stakeholder groups.

Table 1. Key stakeholders groups and targeted messages

 Scientific community	 Healthcare payers	 General public	 Diabetic patients	 Patient advocacy groups	 Policy-and decision-makers
Interest					
Access to scientific knowledge; synergies	Cost-effective treatment for clients	Improvement for society as a whole	Effective treatment for diabetes	Improved treatment of diabetic patients.	Safe, ethical and effective therapies
Message					
“VANGUARD’s bioartificial pancreas will reduce risks and improve success rates of islet transplantation.”	“Bioartificial pancreas transplantation will reduce costs of disease management and occurrence of complications.”	“VANGUARD will offer a cure for type 1 diabetes. This shows how research is moving forward in Europe.”	“VANGUARD’s bioartificial pancreas will improve patients’ quality of life and overcome disadvantages of current therapies.”	“The use of a bioartificial pancreas increases the success rate of islet transplantation and replaces current therapies.”	“The use of bioartificial pancreas will minimize negative effects of diabetes on employment and education, in line with ethical principles.”

All VANGUARD’s stakeholder engagement, communication, outreach and dissemination activities are executed as part of the work package (WP) 9 *Stakeholder engagement, dissemination and exploitation*. Details on the planned activities and how these will be implemented are documented as part of the deliverable D9.2 *Stakeholder Engagement and Dissemination Plan (SEDP)*.

The deliverable D9.4 VANGUARD Communication Portfolio documents the communication content currently available to internal and external stakeholders. As different stakeholder groups are interested in different content and messages from the VANGUARD project we have defined three main sections which, combined, create the VANGUARD Communication Portfolio. Further, as all activities defined as part of the SEDP will be implemented over the course of the five-year project we have opted for an online portfolio which can continuously be updated with new content and materials. The key areas of the Communication Portfolio can be found online via the links below:

- **Outreach** (public access): Communication and outreach focus, targeted towards patients, the general public and media (Public access).
- **Outcomes** (public access): Dissemination oriented and targeted towards the scientific community, healthcare and patient advocacy groups.
- **Members area** (closed access) communication: For internal stakeholders of the VANGUARD network, supporting materials to facilitate the implementation of communication and dissemination measures.

The main aim of the Communication Portfolio and the related communication and dissemination material is to create identity, consistency and awareness of the VANGUARD project and to have material accessible for all stakeholder groups (Task 9.1).

 Project Number 874700	Title VANGUARD Communication Portfolio	Deliverable Number D9.4
		Version 2

2 Communication Portfolio Areas

The VANGUARD Communication Portfolio has been divided into three main areas, content of the various areas are described in the following sections.



Outreach (public access):
Communication and outreach.



Outcomes (public access):
Dissemination of results.



Members area (closed access):
For internal stakeholders of the VANGUARD network

2.1 Outreach

The **Outreach** area is publicly available on the VANGUARD project website and documents all communication- and outreach-related materials. All planned outreach and communication activities aim to create awareness, connect with key stakeholders, and generally establish a network with the general public, the media, patients and patient organisations. Creating awareness and interest in the VANGUARD project and its objectives is important as VANGUARD aims to achieve a breakthrough in the research on curing type 1 diabetes. If successful, the project's results should be translated into a clinical reality as fast as possible. As such, major changes require time to be assimilated and integrated, future patients and early adopters will be given the opportunity to get familiar with the VANGUARD solution. The outreach area currently consists of four main sections described in the following sections.

2.1.1 VANGUARD in the media

VANGUARD has received media interest from various news and interest groups which have contacted partners in order to receive further information which they can publish on their channels. The media's interest has further contributed to raising awareness of VANGUARD to the project's stakeholders and society in general. The VANGUARD in the media shows selected uptake of the VANGUARD press release by national and international media channels.



Figure 1: HORIZON – The EU Research & Innovation Magazine, Lab grown and do-it-yourself: two emerging routes to an artificial pancreas. Published 23.07.2020




Figure 2: CORDIS – EU research results, New research on a promising treatment against type 1 diabetes funded by the European Commission. Published 18.02.2020

 Project Number 874700	Title VANGUARD Communication Portfolio	Deliverable Number D9.4
		Version 2

- [VANGUARD – European consortium to develop a new generation cell therapy: Bioartificial Pancreas to Cure Type 1 Diabetes](#). Published by partner KGM, 2020.
- [Il punto in Europa sulla sostituzione delle cellule beta per la terapia del diabete](#) (Italian). Published by partner OSR, 03.02.2020.
- [Nova pesquisa sobre um tratamento promissor contra o diabetes tipo 1 financiado pela Comissão Europeia](#) (Portuguese). Published by Tia Beth, 18.02.2020
- [Verso la cura: Vanguard, nuova ricerca su un trattamento promettente contro il diabete di tipo 1 finanziata dalla Commissione europea](#) (Italian) Published by Il mio diabete, 19.02.2020.
- [EU project to develop a bio-artificial lab-grown pancreas](#). Published by Innovation News Network, 24.07.2020.
- [Vanguard per il diabete tipo 1: pancreas artificiale attecchito in laboratorio e fai-da-te: due vie emergenti per la cura del T1D](#) (Italian). Published by Il mio diabete, 24.07.2020.
- [Gekweekte alvleesklier: wens of grens?](#) (Dutch). Published by amazingerasmusmc, 01.10.2020.


2.1.2 Public Relations

The first press release for VANGUARD was published in M2 to introduce the project as a whole. Additionally, an open letter in form of a patient sheet with information for patients and their relatives was published in M7 to manage expectations. Further press releases are expected based on when key results and outcomes within VANGUARD are achieved.

VANGUARD Press Release 1 – [New research on a promising treatment against type 1 diabetes funded by the European Commission](#). Published 18.02.2020

VANGUARD Patient Sheet – [Information for patients and their relatives](#). Published 22.07.2020

Project no. 874700
Date: 18 February 2020



New research on a promising treatment against type 1 diabetes funded by the European Commission

More than 40 million individuals worldwide are affected by type 1 diabetes, which is the most common chronic disease in children and adolescents. Today's primary treatment for diabetes is insulin therapy, which requires multiple injections every day to control a person's blood sugar levels. This can potentially lead to chronic complications such as kidney-related issues (nephropathy), visual impairments (retinopathy) and ischemic heart disease. Beta-cell replacement, done either by pancreas or islet transplantation, is a valid alternative to daily injections, as it restores the possibility to control blood sugar levels (glucose). However, pancreas or islet transplantations rely on organ donors and require lifelong anti-rejection medication to avoid the rejection of the transplanted organ or cells. The process is also associated with complications and is currently only offered to a limited number of patients with severe forms of the disease.

Within the framework of a European funded H2020 project, VANGUARD aims to develop a cure for type 1 diabetes available to a larger group of patients. The VANGUARD project will use advanced tissue engineering techniques to generate a bioartificial pancreas, with the aim to propose a novel cell-based treatment to type 1 diabetes that overcomes the limitations inherent to current therapies. Working on this innovative solution is a multidisciplinary team of researchers from Switzerland, Italy, France, Germany and The Netherlands, led by Dr. Ekaterine Berishvili from the University of Geneva, Department of Surgery. According to Dr. Berishvili "the VANGUARD multidisciplinary team will bring regenerative medicine for type 1 diabetes from bench to bedside". In total, the project brings together outstanding expertise from six academic institutions with leading scientists in bioengineering, transplantation, gene therapy, immunology and ethics, two SMEs and an NGO.


VANGUARD's bioartificial pancreas has the potential to improve the success rate of beta-cell replacement therapies with exceptional advantages in terms of efficacy and safety. The treatment of a large number of patients with type 1 diabetes could dramatically reduce the financial burden of the disease, mostly associated with the healthcare costs of chronic secondary complications of diabetes.

The VANGUARD project officially started and had its kick-off last month in January 2020, in conjunction with the annual symposium of the European Pancreas and Islet Transplant Association. Representatives from the nine project partners discussed the start of the research activities and the path towards what has the potential to be a real breakthrough towards a cure for type 1 diabetes.

Page 1 of 2

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 874700

Project no. 874700
Date: 22 July 2020



Information for patients and their relatives

Dear followers of the VANGUARD project,

Since the VANGUARD website has been activated, we have received many messages from patients and their families enquiring about the possibility to enroll in the study.

We are grateful to have so many people interested in the project and following our progress. At the same time, we feel a great responsibility toward people living with type 1 diabetes and their families.

At this time, we are at the very start of the VANGUARD project. We have had a small delay in getting started due to the COVID-19 pandemic. In the coming years we will work on developing the individual parts of the VANGUARD product. Once the separate parts are ready, we will assemble them to form the complete bioartificial pancreas. In order to understand whether the individual parts and the assembled product work, we will carry out our research on small animals. This development phase will take 5 years. After this we hope to start studying how the bioartificial pancreas works in humans/people.

Before we can test the bioartificial pancreas in humans, we need to show that it works (i.e. that it effectively produces insulin) and that it is safe to use in humans. The whole VANGUARD consortium is committed to meet these challenges.

As part of this project we will be investigating the patient perspective on this product. What are patients' thoughts, concerns or information needs? We will study this so we can take these things into consideration in the next phase of human testing. When we start this part of our research, we will post information on how you can participate on our social media platforms. We hope you will get involved!

In the meantime, we will post news on the VANGUARD project on our social media platforms to keep you informed on our progress and the milestones we have reached.

Thank you for your interest in the VANGUARD project and be assured that the whole VANGUARD team is committed to deliver the bioartificial pancreas for you in the hope of offering a new treatment for Type 1 diabetes in the future.

Ekaterine Berishvili, MD, PhD, project coordinator

Page 1 of 1

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 874700

 Project Number 874700	Title VANGUARD Communication Portfolio	Deliverable Number D9.4
		Version 2

2.1.3 Visual elements

VANGUARD uses the advantages of illustration by creating several graphics to explain scientific facts in an easy-to-understand way for lay audiences.

A [graphic](#) showing the scientific approach of VANGUARD has been created (M3).




Figure 3. Initial visualisation of the VANGUARD process

Additionally, a first infographic on the new cell therapy for type 1 diabetes has been created (Figure 4). All graphics are included on the project website and further shared through the VANGUARD social media channels (see 2.1.4). Partners are free to use or request graphics for all their communication activities. accelCH will create the graphics in collaboration with the project partners.

1 WHAT IS IT?

Type 1 diabetes is an autoimmune condition in which the body is not able to produce insulin and regulate blood sugar levels.

More than **40 million individuals** worldwide are affected making it the most common chronic disease.

The condition **can develop at any age**, with no known way to prevent it.

2 UNSATISFACTORY TREATMENT OPTIONS

Insulin therapy
 Today's **primary treatment** for diabetes is insulin therapy, which requires multiple injections every day to control a person's blood sugar levels.
 This **cannot prevent chronic complications** such as kidney-related issues, visual impairments and ischemic heart disease.

Beta-cell replacement
 Pancreas or islet transplantation are **valid alternatives** to daily injections, as they restore the possibility to control blood sugar levels.
 However, **they rely on organ donors and require lifelong anti-rejection medication** to avoid the rejection of the transplanted organ or cells.

3 THE VANGUARD PROJECT

VANGUARD aims to develop a **cure** for type 1 diabetes by **generating a bioartificial pancreas** that overcomes the limitations inherent to current therapies.

In the coming years VANGUARD will develop the individual parts and once these are ready, they will be assembled to form the **complete bioartificial pancreas**.

Once tested, the VANGUARD project could improve the **success rate of beta-cell replacement therapies** with exceptional advantages in terms of efficacy and safety.

VANGUARD
 Follow us for more information

✉ project@vanguard-project.eu 🐦 @vanguard_h2020
 💻 www.vanguard-project.eu 📘 @vanguard.h2020

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 874700

Figure 4: VANGUARD infographic

 Project Number 874700	Title VANGUARD Communication Portfolio	Deliverable Number D9.4
		Version 2

2.1.4 Social media

Currently, VANGUARD has two own social media channels including a [Facebook Group](#) and a [Twitter account](#) which are kept up-to-date by UNIGE and accelCH. All partners contribute to the social channels by either delivering content for the channels or by resharing content to reach a larger audience. The social media channels have been embedded in the [Outreach](#) area to make it easier for stakeholders to access the content and follow VANGUARD via their preferred medium.



Figure 5: VANGUARD [Twitter account](#)




Figure 6: VANGUARD [Facebook Group](#)

	<p style="text-align: center;">Title</p> <p style="text-align: center;">VANGUARD Communication Portfolio</p>	<p style="text-align: center;">Deliverable Number D9.4</p>
<p style="text-align: center;">Project Number 874700</p>		<p style="text-align: center;">Version 2</p>

2.2 Outcomes

The [Outcomes](#) area of the Communication Portfolio focuses on disseminating VANGUARD results. In the scientific context, results are mainly shared through publications in scientific journals and conference presentations. UNIGE and KGM will screen all documents for possibilities of IP protection prior to publishing. In addition, in line with the Grant Agreement (Article 29.1), all partners will be given advance notice of at least 45 days whenever results are to be disseminated or submitted for publication.

2.2.1 VANGUARD workshops

A number of stakeholder-focused events have been planned to be implemented over the course of the VANGUARD project. The first VANGUARD workshop on *Ethics of early clinical trials in regenerative medicine in transplantation* was organised online by Erasmus MC in M26. The event was promoted via the project website as well as social media channels to attract external stakeholders interested in ethics to join the virtual workshop. This workshop brought together 74 participants and experts in the fields of regenerative medicine and ethics to discuss these ethical challenges. A recording of the workshop is available on the website.



Figure 7: Recording from the [ethics workshop](#)

 Project Number 874700	Title VANGUARD Communication Portfolio	Deliverable Number D9.4
		Version 2

2.2.2 Scientific publications

The VANGUARD consortium is committed to open access publishing in line with the rules set out in the Grant Agreement and aims to have their results published in peer-reviewed journals with a high impact factor (above six) whenever possible. To date, VANGUARD partners have published results from the project in 14 publications which are listed below. Further publications as well as conference posters, proceedings and presentations will be added when available.

All VANGUARD publications include the acknowledgement to Horizon 2020 according to Article 29.4 of the Grant Agreement.

1. La Presse Médicale, 2022
[From islet of Langerhans transplantation to the bioartificial pancreas](#)
Berney T, Wassmer CH, Lebreton F, Bellofatto K, Mar-Fonseca L, Bignard J, Hanna R, Peloso A, Berishvili E
2. TRANSPLANT INTERNATIONAL, 2022
[Bioengineering the Vascularized Endocrine Pancreas: A Fine-Tuned Interplay Between Vascularization, Extracellular-Matrix-Based Scaffold Architecture, and Insulin-Producing Cells](#)
Pignatelli C, Campo F, Neroni A, Piemonti L, and Citro A.
3. STEM CELL RESEARCH & THERAPY, 2022
[Organoids: a systematic review of ethical issues](#)
de Jongh D, Massey E, and Bunnik E M.
4. TRANSPLANT INTERNATIONAL, 2022
[Ethics of Early Clinical Trials of Bio-Artificial Organs](#)
Bunnik E M, de Jongh D, and Massey E.
5. CURRENT OPINION IN ENDOCRINE AND METABOLIC RESEARCH, 2022
[Advances and challenges of endocrine pancreas bioengineering](#)
Hanna R and Berishvili E.
6. TRANSPLANT INTERNATIONAL, 2022
[Bio-Engineering of Pre-Vascularized Islet Organoids for the Treatment of Type 1 Diabetes](#)
Wassmer CH, Lebreton F, Bellofatto K, Perez Lisa, Cottet-Dumoulin D, Andres A, Bosco D, Berney T, Othenin-Girard V, Martinez de Tejada B, Cohen M, Olgasi C, Follenzi A, and Berishvili E.
7. STEM CELL REVIEW AND REPORTS, 2021
[Mechanisms of Immunomodulation and Cytoprotection Conferred to Pancreatic Islet by Human Amniotic Epithelial Cells](#)
Lebreton F, Hanna R, Wassmer CH, Bellofatto K, Perez L, Othenin-Girard V, Martinez de Tejada B, Cohen M, and Berishvili E.
8. MOLECULAR THERAPY - METHODS & CLINICAL DEVELOPMENT, 2021
[Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device](#)
Olgasi C, Borsotti C, Merlin S, Bergmann T, Bittorf P, Adewoye A B, Wragg N, Patterson K, Calabria A, Benedicenti F, Cucci A, Borchiellini A, Pollio B, Montini E, Mazzuca D M, Zierau M, Stolzing A, Toleikis P, Braspenning J, and Follenzi A.
9. NATURE METABOLISM, 2020
[I've got you under my skin](#)
Berney T, Berishvili E.

 Project Number 874700	Title VANGUARD Communication Portfolio	Deliverable Number D9.4
		Version 2

10. TRANSPLANT INTERNATIONAL, 2020
[Generation of insulin-secreting organoids: a step toward engineering and transplanting the bioartificial pancreas](#)
Wassmer CH, Lebreton F, Bellofatto K, Bosco D, Berney T, and Berishvili E.
11. CURRENT DIABETES REPORTS, 2020
[Immunomodulatory Properties of Amniotic Membrane Derivatives and Their Potential in Regenerative Medicine](#)
Wassmer CH and Berishvili E.
12. STEM CELL REVIEWS AND REPORTS, 2020
[Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy](#)
Berishvili E, Kaiser L, Cohen M, Berney T, Scholz H, Floisand Y, and Mattsson J.
13. CELL TRANSPLANTATION, 2020
[Engineering of Primary Pancreatic Islet Cell Spheroids for Three-dimensional Culture or Transplantation: A Methodological Comparative Study](#)
Wassmer CH, Bellofatto K, Perez L, Lavallard V, Cottet-Dumoulin D, Ljubicic S, Parnaud G, Bosco D, Berishvili E, and Lebreton F.
14. CELL4, 2020
[Targeting Toll-Like Receptor 4: a promising strategy to prevent type 1 diabetes occurrence or recurrence](#)
Alibashe-Ahmed M, Berney T, Giovannoni L, Berishvili E.
[Link to corrigendum](#) – incorrect funding

In addition to the open-access links to all scientific publications, the consortium has decided to write short descriptions of each publication for the lay audience to make the content easier to understand and more accessible to a larger audience.

2.2.3 Public Reports

VANGUARD continuously reports its results and progress to the European Commission. Some of these reports, called deliverables are public and once submitted will be made available in the outcomes area.

- D9.1 Project website, due 29/02/2020, [download available](#)
- D9.4 VANGUARD Communication Portfolio, due 30/06/2022
- D2.1 ELSA Training Manual, due 31/12/2022
- D2.2 Guidelines on ethical, social, legal and psychological aspects of VANGUARD, due 31/12/2022
- D9.3 VANGUARD Stakeholder Engagement and Dissemination Assessment Reports, due 31/12/2023
- D9.7 Policy brief, due 31/12/2024
- D9.8 Final project event and EU Parliament workshop, due 31/12/2024

 Project Number 874700	Title VANGUARD Communication Portfolio	Deliverable Number D9.4

2.3 Members' area

A number of communication-supporting materials were created for internal use and are not publicly available to external stakeholders as the content is targeted towards VANGUARD project partners. The project's internal material has been made available via the [VANGUARD member's area](#) and aims at facilitating the project partners' internal communication within the project.

2.3.1 Project Handbook

VANGUARD needs a flexible communication instrument to provide up-to-date and consistent information to its Beneficiaries regarding their participation in a Horizon 2020-funded project. The Beneficiaries need a document to inform themselves about the best practices and the most important rules to follow. For this, accelCH has set up an internal project handbook which includes guidelines and FAQ information sheets on specific topics related to project management and communications.



Figure 8: Screenshots from the VANGUARD Project Handbook

2.3.2 Stakeholder Engagement and Dissemination Plan

The deliverable D9.2 *Stakeholder Engagement and Dissemination Plan (SEDP)* is a plan on the strategy and measures defined within the VANGUARD project to support all stakeholder engagement, communication and dissemination measures. The SEDP offers all project partners the opportunity to follow the plan for implementation of all activities linked to work package 9.




Figure 9: Screenshots from the VANGUARD Stakeholder Engagement and Dissemination Plan

 Project Number 874700	Title VANGUARD Communication Portfolio	Deliverable Number D9.4
		Version 2

2.3.3 Templates

Pre-designed templates for a range of materials have been made available to all VANGUARD partners. The templates created for the most common types of documents offer the project partners a basis document which can easily be adapted to the information they wish to disseminate while still keeping in line with the overall visual identity of the VANGUARD project. Templates make it easier and more efficient to follow the above design guidelines.



Figure 10: VANGUARD templates

3 Outlook

The content and specific areas of the Communication Portfolio will be updated on a regular basis to include the latest updates and materials created for VANGUARD. The specific activities that will be implemented and developed are documented in the SEDP. This includes specific outreach activities such as explainer videos, patient engagement events, further infographics and press releases and results-oriented dissemination activities such as conference presentations and posters and the organisation of own events.

All activities aim to achieve the stakeholder engagement, communication and dissemination objectives defined in the SEDP. They have been planned based on the current knowledge of the target groups, the expected project progress and experience from previous projects.

Over the timespan of VANGUARD, project- or target group-related factors may change. Some activities will prove effective, others less. As the consortium is dedicated to reaching maximum impact, repeated evaluation and adjustment are necessary, based on feedback loops per activity. The monitoring, evaluation and improvement procedure will take place at relevant points of time during the project or periodically, depending on the activity's evaluation method.

 Project Number 874700	Title VANGUARD Communication Portfolio	Deliverable Number D9.4 <hr/> Version 2
---	--	--

Annex: Screenshots of the Communication Portfolio



Outreach

VANGUARD in the media

HORIZON - The EU Research & Innovation Magazine. Lab grown and do-it-yourself: two emerging routes to an artificial pancreas. Published 23.07.2020

CORDIS - EU research results. New research on a promising treatment against type 1 diabetes funded by the European Commission. Published 18.02.2020

- VANGUARD - European consortium to develop a new generation cell therapy: Bioartificial Pancreas to Cure Type 1 Diabetes. Published by partner KOM. 2020.
- Il punto in Europa sulla sostituzione delle cellule beta per la terapia del diabete (Italian). Published by partner OBR. 03.02.2020.
- Nova pesquisa sobre um tratamento promissor contra o diabetes tipo 1 financiado pela Comissão Europeia (Portuguese). Published by Tia Beth. 18.02.2020
- Vetro la cura: Vanguard, nuova ricerca su un trattamento promettente contro il diabete di tipo 1 finanziata dalla Commissione europea (Italian). Published by Il mio diabete. 19.02.2020
- EU project to develop a bio-artificial lab-grown pancreas. Published by Innovation News Network. 24.07.2020.
- Vanguard per il diabete tipo 1: pancreas artificiale attecchito in laboratorio e fa-da-te: due vie emergenti per la cura del T1D (Italian). Published by Il mio diabete. 24.07.2020.
- Geleekste alveeskler: wens of grens? (Dutch). Published by amazingerasmus. 01.10.2020.

Public Relations

VANGUARD Press Release 1 - New research on a promising treatment against type 1 diabetes funded by the European Commission. Published 18.02.2020


VANGUARD Patient Sheet - Information for patients and their relatives. Published 22.07.2020

VANGUARD infographic 2021 - New cell therapy for type 1 diabetes. Published 11.06.2021


This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 874700

Figure 11: Screenshot [Outreach](#) page

 Project Number 874700	Title VANGUARD Communication Portfolio	Deliverable Number D9.4
		Version 2



[Project](#) | [Content](#) | [News & Events](#) | [Contact](#)




Outcomes

VANGUARD WORKSHOPS

Ethics of early clinical trials in regenerative medicine in transplantation | Online, Thursday 3 February 2022

Bio-artificial organs and bio-engineered or bio-printed tissues for transplantation in humans are rapidly being developed. It is anticipated that some applications will be ready for clinical testing in the near future. How can first-in-human clinical trials be conducted in a safe and responsible manner? What are ethical points to consider for early clinical trials of regenerative medicine in transplantation? This workshop brings together experts in the fields of regenerative medicine and ethics to discuss these ethical challenges.

This video shows the full recording of the VANGUARD Ethics workshop held online, Thursday 3 February 2022 from 16:00-18:00.



SCIENTIFIC PUBLICATIONS

Below is a list of all accepted VANGUARD scientific publications available to date. Further publications as well as conference posters, proceedings and presentations will be added when available.


1. TRANSPLANT INTERNATIONAL, 2022
Bio-Engineering of Pre-Vascularized Islet Organoids for the Treatment of Type 1 Diabetes
Wassmer CH, Labreton F, Bellefatto K, Perez L, Cortes-Dunhoulin G, Andreis A, Bosco D, Berny T, Dherin-Giard K, Martinez de Tejada B, Cohen M, Ogazi C, Folero A, Bershtvei E.
2. STEM CELL REVIEW AND REPORTS, 2021
Mechanisms of Immunomodulation and Cytoprotection Conferred to Pancreatic Islet by Human Amniotic Epithelial Cells
Labreton F, Hanna S, Wassmer CH, Bellefatto K, Perez L, Dherin-Giard K, Martinez de Tejada B, Cohen M, Bershtvei E.
3. NATURE METABOLISM, 2020
I've got you under my skin
Berny T, Bershtvei E.
4. TRANSPLANT INTERNATIONAL, 2020
Generation of insulin-secreting organoids: a step toward engineering and transplanting the bioartificial pancreas
Wassmer CH, Labreton F, Bellefatto K, Bosco D, Berny T, Bershtvei E.
5. CURRENT DIABETES REPORTS, 2020
Immunomodulatory Properties of Amniotic Membrane Derivatives and Their Potential in Regenerative Medicine
Wassmer CH, Bershtvei E.
6. STEM CELL REVIEWS AND REPORTS, 2020
Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy
Bershtvei E, Kaiser L, Cohen M, Berny T, Dohetz H, Fjorstad T, Mattsson J.
7. MEDICAL SCIENCES, 2020
Organoides secretoras d'insulina - (de) «super-islets» comme premier pas vers le pancréas bioartificiel
Labreton F, Wassmer CH, Bellefatto K, Berny T, and Bershtvei E.
8. CELL TRANSPLANTATION, 2020
Engineering of Primary Pancreatic Islet Cell Spheroids for Three-dimensional Culture or Transplantation: A Methodological Comparative Study
Wassmer CH, Bellefatto K, Perez L, Lavillard V, Cortes-Dunhoulin G, Ljubcic S, Theraud G, Bosco D, Bershtvei E, Labreton F.

PUBLIC REPORTS

VANGUARD continuously reports its results and progress to the European Commission. Some of those reports (called "Deliverables") are public and once submitted are made available for download here:

- D9.1 Project website, due 29/10/2020, download available
- D9.4 VANGUARD Communication Portfolio, due 30/06/2022
- D2.1 ELSA Training Manual, due 31/12/2022
- D2.2 Guidelines on ethical, social, legal and psychological aspects of VANGUARD, due 31/12/2022
- D9.3 VANGUARD Stakeholder Engagement and Dissemination Assessment Reports, due 31/12/2023
- D9.7 Policy brief, due 31/12/2024
- D9.8 Final project event and EU Parliament workshop, due 31/12/2024

* Please note that these deliverables are undergoing review and acceptance processes. At this stage this deliverable reflects only the author's view and the European Commission is not responsible for any use that may be made of the information it contains.



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 874700

[Home](#) | [Privacy Policy](#) | [Contact](#)

Figure 12: Screenshot Outcomes page